represents the HCFA data reported in an October 2000 JAMA article. Data was collected on
750 patients per state, and although that is a modest sample, it was a very rigorous chart
review. These patients came into the hospital with an AMI, and all of them were screened
so that all of these interventions should have occurred in each of these patients. The
right column indicates where we should be “optimally.” The left-column
indicates where we are nationwide. As we consider the number of AMI’s annually, a 15%
treatment gap for aspirin is far-reaching.
Cholesterol was not measured in the HCFA
survey, and the data comes from the National Registry for Myocardial Infarction. It
represents about 100,000 patients and is from July 2000. At that time, it was reported
that 37% of patients were leaving the hospital on a lipid-lowering intervention. We know
that about 96% of patients leave the hospital with an elevated lipid level and would
benefit from a cholesterol-lowering intervention. Again, a substantial gap in treatment.